



COX & SMITH
INCORPORATED
ATTORNEYS ♦ COUNSELORS

112 East Pecan Street
Suite 1800
San Antonio, Texas 78205-1521
(210) 554-5500
Fax (210) 226-8395
www.coxsmith.com

RECEIVED

MAY 14 2001

TECH CENTER 1600/2900

Writer's Direct Number
(210) 554-5302

Writer's E-Mail Address
wbbarnes@coxsmith.com

May 9, 2001

BOX RESPONSE - NO FEE
Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

Re: United States Patent Application, Serial No.: 09/612,894
Entitled: **COMPOSITIONS AND METHODS FOR
REGULATION OF STERIODOGENESIS**
TTU D-0210
Our Reference No.: 18491.40

Sir:

Enclosed for filing with the papers of the above-referenced application are the following:

1. Response to Office Action and Amendment; and
2. Acknowledgment Post Card.

The undersigned believes that no fee is required for this submission. However, if a fee is required, the Commissioner is hereby authorized to charge any such fee to Deposit Account No. 03-3483.

Respectfully submitted,

W. Bradley Barnes
Reg. No. 46,538

EXPRESS MAIL "Post Office to Addressee"
Mailing Label No.: EL411331208US
Date of Deposit: May 9, 2001

WBB/lah/355807 01
Enclosures

cc: Mr. H. Walter Haussler (w/encls.)
ic: Mr. Court B. Allen [Firm] (w/o encl.)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stocco, et al.

Serial No. 09/612,894

Title: **COMPOSITIONS AND METHODS
FOR REGULATION OF
STERIOGENESIS**



§
§
§
§
§
§
§

Atty Docket No. 18491.40

Filing Date: 07/10/00

Group Art Unit: 1656

Examiner: J. Riley

RESPONSE TO OFFICE ACTION AND AMENDMENT

Box Response – No Fee
Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

RECEIVED

MAY 14 2001

TECH CENTER 1600/2900

Madam:

Applicant hereby timely responds to the Office Action dated February 14, 2001 by filing this Response within the three (3) month shortened statutory time period set by the Examiner. No fees are believed due for the submission of this paper; however, should any fees be required for any reason, the Commissioner is authorized to deduct any such fees from Deposit Account No. 03-3483.

AMENDMENT

In the Claims:

Please amend the claims as follows:

14. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence as set forth in SEQ ID NO: 2

15. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence extending from amino acid methionine at position 48 through amino acid cysteine at position 284 in SEQ ID NO: 2.

17. [Amended] A purified polypeptide [having] consisting of a contiguous [an] amino acid sequence in accordance with SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8.

37. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence [essentially as set forth in] having a 70 to 99% identity to SEQ ID NO: 2

39. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence [essentially] having a 70 to 99% identity to the amino acids as set forth from amino acid methionine at position 48 through amino acid cysteine at position 284 of SEQ ID NO: 2.

40. [Amended] A purified polypeptide [having] consisting of a contiguous [an] amino acid sequence [essentially] having a 70 to 99% identity to [as set forth in] one of the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.

41. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence as set forth in SEQ ID NO: 18.

43. [Amended] A purified steroidogenic acute regulatory protein [having] consisting of a contiguous [an] amino acid sequence [essentially] having a 70 to 99% identity to [as set forth in] SEQ ID NO: 18.

REMARKS

I. Status of the Claims

Claims 14 - 17 and 37 - 43 are pending in the Application.

Claims 1 - 13 and 18 - 36 have been cancelled.

Claims 14 - 17 and 37 - 40 have been rejected.